FDA Determines Regulatory Review Period for FLUCELVAX Patent Extension Application

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for FLUCELVAX, a human biological product, and is publishing this notice as required by law. The determination was made due to a patent extension application submitted to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce.